Therapy-induced Toxicity of the Lungs: An Overview
Pulmonary toxicity induced by novel antineoplastic agents has not been well characterized because of the simultaneous or sequential use of drugs and a multimodality therapeutic approach. To further investigate this topic, relevant studies were identified through Medline. The generic names of novel a...
Saved in:
Published in | Anticancer research Vol. 29; no. 2; pp. 631 - 639 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Attiki
International Institute of Anticancer Research
01.02.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Pulmonary toxicity induced by novel antineoplastic agents has not been well characterized because of the simultaneous or sequential
use of drugs and a multimodality therapeutic approach. To further investigate this topic, relevant studies were identified
through Medline. The generic names of novel antineoplastic agents and the key words pulmonary toxicity, dyspnea and pneumonitis
were used for the search. References from the articles identified were also reviewed for additional sources. Most novel antineoplastic
drugs may induce pulmonary toxicity. The most recognized patterns of lung toxicity consist of unspecified dyspnea and interstitial
lung disease (ILD). Exclusion diagnosis of possible underlying diseases is necessary. Genetic predisposition, autoimmune conditions
or superimposed disease may also be involved in the development of lung toxicity. Conclusion: Clinicians should be aware of
potential pulmonary toxicity as a complication in the treatment of cancer and focus on its early detection or prediction. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0250-7005 1791-7530 |